Management of the primary cutaneous lymphomas.
Cutaneous lymphomas are rare and, although some are a manifestation of systemic lymphoma, the majority arise primarily from the skin. These primary cutaneous lymphomas comprise both T- and B-cell subtypes and represent a wide spectrum of disorders, which at times can be difficult to diagnose and classify. Classical therapeutic strategies include topical corticosteroids, phototherapy, radiotherapy, retinoids, extracorporeal photopheresis, topical chemotherapy, systemic chemotherapy and biological response modifiers. Newer therapies include the synthetic retinoid bexarotene, the immunotoxin conjugate denileukin diftitox, interleukin-12 and monoclonal antibodies such as alemtuzumab and rituximab.
Prince
H Miles
HM
Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. miles.prince@petermac.org
McCormack
Christopher
C
Ryan
Gail
G
O'Keefe
Rod
R
Seymour
John F
JF
Baker
Chris
C
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001707:Biopsy, Needle; D003131:Combined Modality Therapy; D004502:Education, Medical, Continuing; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007155:Immunologic Factors / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008297:Male; D009182:Mycosis Fungoides / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D010789:Phototherapy / Q000379:methods; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012751:Sezary Syndrome / Q000401:mortality / Q000473:pathology / Q000628:therapy; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D007155:Immunologic Factors